Skip to main content
Fig. 3 | Journal for ImmunoTherapy of Cancer

Fig. 3

From: A rare population of tumor antigen-specific CD4+CD8+ double-positive αβ T lymphocytes uniquely provide CD8-independent TCR genes for engineering therapeutic T cells

Fig. 3

TCR avidity and tumor recognizing capacity of TCR gene-transduced T cells. a TCR transduction efficiency on normal donor PBMC was determined by tetramer staining. b TCR avidity of TCR-transduced CD8+ and CD4+ T cells against NY-ESO-1157-165 peptide-pulsed A*02+ EBV-B cells was determined by intracellular IFN-γ staining. The data indicates means ± SD from duplicate experiment. c Representative flow cytometry plots of IFN-γ production on CD8+ and CD8− (CD4+) T cells against A375 is shown. d TCR avidity of 19305DP-TCR, murine TCR (mTCR) or affinity-enhanced TCR (LY)-transduced CD8+ and CD4+ T cells was determined against NY-ESO-1157-165 peptide-pulsed A*02+ EBV-B cells by intracellular IFN-γ staining. Data are represented as % relative IFN-γ production at different peptide concentration as compared to % IFN-γ production at 10 μM. e Recognition of the indicated melanoma cell lines by 19305DP-TCR-transduced T cells was compared to T cells transduced with LY or mTCR recognizing the same NY-ESO-1-epitope region

Back to article page